WHO Recommends Two New Ebola Vaccine Candidates for DRC Trial

The addition of ChAdOx1 and mRNA-1469 broadens the platform mix in the TUMAINI trial beyond whatever candidates were already under study, which matters because vaccine platform diversity is itself a hedge against a single approach underperforming in the field. The near-term readout is on the treatment side, not the vaccines, so the vaccine question stays open well beyond the preliminary treatment results expected in the coming months. Whether the expanded candidate list translates into a faster or more durable response for DRC outbreak preparedness is the open question, with the vaccine data not due until early 2027.